Organon (OGN) | Stock Overview & Key Data
Organon Performance Comparison
Stock Range
Today's Range
Low: $11.00
High: $11.29
on October 3, 2025
52 Week Range
Low: $8.01
High: $19.05
on May 14, 2025
on October 31, 2024
All-Time High: $39.47 on February 28, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.9B
EPS
2.69
P/E Ratio (TTM)
4.09
Forward P/E
2.60
P/B Ratio
3.90
PEG Ratio
-0.16
Div. Yield
8.50%
ROE
159.64%
Beta
0.595
Debt to Equity
1,213.64
Financial Highlights
Profitability
Gross Margin
54.83%
Operating Margin
21.08%
Profit Margin
11.15%
Returns and Earnings
Return on Assets (TTM)
6.62%
Return on Equity (TTM)
159.64%
EBITDA
$1.7B
Net Income (TTM)
$700.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$24.36
Quarterly Revenue Growth (YoY)
-0.80%
Quarterly Earnings Growth (YoY)
-25.60%
Dividend Information
Last 12-Month Dividend
$0.84
Current Dividend Yield
8.50%
3-Year Average Dividend Yield
1.46%
3-Year Average Annual Dividend
$1.03
3-Year Total Dividends
$3.08
Ex-Dividend Date
February 24, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Organon OGN | 2.86B Mid-cap | 7.84% | 12.00% | 10.54% | -23.81% | -26.40% | -39.80% | -54.14% | -66.89% |
| Eli Lilly and LLY | 760.94B Mega-cap | 15.92% | 13.83% | 7.58% | 6.44% | 7.94% | -5.33% | 157.11% | 435.36% |
| Johnson & Johnson JNJ | 454.31B Mega-cap | 4.97% | 5.98% | 20.92% | 18.03% | 30.98% | 17.69% | 17.75% | 24.95% |
| AbbVie ABBV | 413.22B Mega-cap | 6.03% | 10.41% | 23.58% | 16.00% | 30.36% | 20.39% | 68.57% | 166.72% |
| Merck & Co MRK | 222.78B Mega-cap | 13.53% | 5.95% | 10.21% | 3.24% | -10.06% | -18.75% | 1.82% | 16.31% |
| Amgen AMGN | 160.37B Large-cap | 9.13% | 4.95% | -0.12% | -3.86% | 14.89% | -6.81% | 30.07% | 25.85% |
Ownership & Short Interest
Insider Ownership
0.25%
Institutional Ownership
84.59%
Shares Short
14M
Short Ratio
3.75
Short % of Shares Outstanding
7.02%
Average 10-Day Volume
3M
Average 90-Day Volume
4M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is OGN's 52-week high and low?
- In the last 52 weeks, Organon reached a high of $19.05 (on October 31, 2024) and a low of $8.01 (on May 14, 2025).
- What is the market cap and P/E ratio for OGN?
- Curious about Organon's size and valuation? Its market capitalization stands at 2.86B. When it comes to valuation, the P/E ratio (trailing twelve months) is 4.09, and the forward P/E (looking ahead) is 2.60.
- Does OGN pay dividends? If so, what's the yield?
- Yes, Organon is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 8.50%, and the company has paid an average of $1.03 per share annually over the past 3 years.
- Who are Organon's main competitors or similar companies to consider before investing?
When looking at Organon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY760.94B Healthcare Drug Manufacturers - General -5.33% 157.11% Johnson & Johnson
JNJ454.31B Healthcare Drug Manufacturers - General 17.69% 17.75% AbbVie
ABBV413.22B Healthcare Drug Manufacturers - General 20.39% 68.57% Merck & Co
MRK222.78B Healthcare Drug Manufacturers - General -18.75% 1.82% Amgen
AMGN160.37B Healthcare Drug Manufacturers - General -6.81% 30.07% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Organon & Co.? (e.g., ROE, Debt/Equity)
- To get a sense of Organon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 159.64%, the Debt to Equity ratio from the most recent quarter is 1,213.64, and its Gross Profit Margin stands at 54.83%.
- What is the recent revenue and earnings growth for OGN?
- Looking at Organon's growth, its revenue over the trailing twelve months (TTM) was $6B. Compared to the same quarter last year (YoY), quarterly revenue grew by -0.80%, and quarterly earnings saw a YoY growth of -25.60%.
- How much of OGN stock is held by insiders and institutions?
- Wondering who owns Organon stock? Company insiders (like executives and directors) hold about 0.25% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 84.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.